Davenport Matthew S, Malyarenko Dariya I, Pang Yuxi, Hussain Hero K, Chenevert Thomas L
1 Department of Radiology, University of Michigan Health System, 1500 E Medical Center Dr, B2-A209P, Ann Arbor MI 48109.
2 Department of Urology, University of Michigan Health System, Ann Arbor, MI.
AJR Am J Roentgenol. 2017 Feb;208(2):328-336. doi: 10.2214/AJR.16.16860. Epub 2016 Dec 8.
The purpose of this study is to investigate the effect of gadoxetate disodium administration on arterial phase respiratory waveforms.
From 2013 to 2015, 107 subjects undergoing liver MRI with either gadoxetate disodium (10 mL diluted 1:1 with saline; injection rate, 2 mL/s; n = 40) or gadobenate dimeglumine (0.2 mL/kg; maximum, 20 mL; injection rate, 2 mL/s; n = 67) were enrolled. Respiratory waveforms obtained during unenhanced and dynamic contrast-enhanced phases were filtered by a physicist, who was blinded to contrast agent and imaging phase, to eliminate electronic and cardiac noise using fast Fourier transformation. The average root-mean-square difference of two intrasubject control phases (unenhanced and late dynamic) was termed D1, and the root-mean-square deviation of the arterial phase referent to the control record mean was termed D2. D1, D2, and their difference were compared across agents with the Mann-Whitney U test. Bland-Altman plots were generated for D1 and D2 values.
D1 values were similar for both agents (mean [± SD], 232 ± 203 for gadoxetate vs 201 ± 230 for gadobenate; p = 0.48), indicating similar intercohort baseline breath-holding capability. D2 was greater and more variable for the gadoxetate cohort (438 ± 381) than for the gadobenate cohort (167 ± 167; p < 0.001), indicating larger and more unpredictable respiratory waveform deviations isolated to the arterial phase (subject-level rate, 48% [19/40] for gadoxetate vs 1% [1/67] for gadobenate; p < 0.001). Aberrant respiratory waveform peaks in the arterial phase were usually associated with transient tachypnea (mean maximum arterial phase respiratory rate for the gadoxetate cohort, 27 breaths/min; range, 11-40 breaths/min).
Fixed-dose gadoxetate disodium (10 mL; 1:1 dilution with 10 mL of saline; injection rate, 2 mL/s) transiently reduces breath-holding capacity during the arterial phase and is accompanied by brief transient tachypnea.
本研究旨在探讨钆塞酸二钠给药对动脉期呼吸波形的影响。
2013年至2015年,纳入107例行肝脏MRI检查的受试者,其中40例使用钆塞酸二钠(10 mL用生理盐水1:1稀释;注射速率,2 mL/s),67例使用钆贝葡胺(0.2 mL/kg;最大量,20 mL;注射速率,2 mL/s)。由一位对造影剂和成像阶段不知情的物理学家对未增强期和动态对比增强期获得的呼吸波形进行滤波,使用快速傅里叶变换消除电子和心脏噪声。将同一受试者两个对照阶段(未增强期和延迟动态期)的平均均方根差值称为D1,将动脉期相对于对照记录均值的均方根偏差称为D2。使用曼-惠特尼U检验比较不同造影剂的D1、D2及其差值。生成D1和D2值的布兰德-奥特曼图。
两种造影剂的D1值相似(钆塞酸组均值[±标准差]为232±203,钆贝葡胺组为201±230;p = 0.48),表明不同队列间的基线屏气能力相似。钆塞酸组的D2值(438±381)高于钆贝葡胺组(167±167;p < 0.001)且变异性更大,表明动脉期单独出现的呼吸波形偏差更大且更不可预测(受试者水平发生率,钆塞酸组为48%[19/40],钆贝葡胺组为1%[1/67];p < 0.001)。动脉期异常的呼吸波形峰值通常与短暂性呼吸急促相关(钆塞酸组动脉期最大平均呼吸频率为27次/分钟;范围,11 - 40次/分钟)。
固定剂量的钆塞酸二钠(10 mL;与10 mL生理盐水1:1稀释;注射速率,2 mL/s)在动脉期会短暂降低屏气能力,并伴有短暂的呼吸急促。